V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20169683 | 20134544 | 1.8 | 44.8 | null | 2017-12-12 | 2017-12-12 | ABEMACICLIB + FULVESTRANT | 02 | null | BORTEZOMIB + THALIDOMIDE | 100250789 |
| 20170038 | 20134545 | 1.8 | 79.9 | Palliative (P) | 2020-03-04 | 2020-05-05 | Hydroxycarbamide | 02 | N | RITUXIMAB | 100730681 |
| 20170144 | 20134547 | 0 | 64 | Curative (C) | 2016-04-10 | 2016-08-03 | SCOPE 2 TRIAL | N | N | COSMIC TRIAL | 100538212 |
| 20170223 | 20134548 | 1.77 | 64.1 | null | 2021-02-06 | 2021-02-14 | ECF | 02 | null | GEMCITABINE + OXALIPLATIN | 100854169 |
| 20170452 | 20134549 | 1.71 | 75.1 | Neo-adjuvant (N) | 2020-01-12 | 2020-06-09 | null | N | null | MITOMYCIN | 100554366 |
| 20170818 | 20134550 | 1.75 | 80.7 | Palliative (P) | 2019-09-29 | 2019-09-29 | PHITT D Carboplatin / doxorubicin . | 02 | N | DOXORUBICIN + OLARATUMAB | 100531977 |
| 20171067 | 20134551 | 1.65 | 80.8 | null | 2020-07-19 | 2020-07-19 | LOMUSTINE + MDG | 2 | N | IBRUTINIB | 101456253 |
| 20171250 | 20134552 | 1.79 | 95.8 | Palliative (P) | 2015-08-04 | 2016-10-06 | CAV | 02 | N | DARATUMUMAB | 101195363 |
| 20171289 | 20134553 | 1.75 | 46.2 | Palliative (P) | 2020-06-13 | 2020-06-29 | CISPLATIN + FLUOROURACIL + RT | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 100369528 |
| 20171355 | 20134554 | 1.72 | 88.8 | null | 2018-03-07 | 2018-03-07 | Cetuximab + FLUOROURACIL | 02 | null | OXALIPLATIN + MDG + PANITUMUMAB | 100547999 |
| 20171611 | 20134555 | 1.77 | 64 | null | 2017-05-02 | 2017-05-02 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | null | HEPATOBLASTOMA RELAPSE VI | 100691231 |
| 20171685 | 20134556 | 1.6 | 90.7 | null | 2021-09-29 | 2022-03-12 | Cetuximab + FLUOROURACIL | 02 | N | GEMCITABINE + OXALIPLATIN | 100753451 |
| 20171699 | 20134557 | 1.6 | 74 | null | 2020-03-22 | 2020-03-24 | Cisplatin + Vinorelbine (PO) | 02 | null | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 100133207 |
| 20171755 | 20134558 | 1.71 | 71.7 | null | 2021-03-24 | 2021-04-06 | ACTICCA-1 Trial | 02 | null | HEPATOBLASTOMA VHR BLOCK A CISPLATIN/DOX | 101700585 |
| 20172079 | 20134559 | 1.51 | 77.7 | null | null | 2018-02-15 | CISPLATIN + FLUOROURACIL + Trastuzumab | null | N | HEPATOBLASTOMA HR CARBO/DOX | 100490910 |
| 20172335 | 20134561 | 1.53 | 103 | null | 2019-03-02 | 2019-03-23 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101193831 |
| 20172650 | 20134562 | 1.77 | 47.4 | Neo-adjuvant (N) | 2017-10-06 | 2017-10-22 | ECF | null | N | CISPLATIN + TEYSUNO | 100315898 |
| 20172794 | 20134563 | 1.56 | 0 | Palliative (P) | null | 2020-01-27 | CAPECITABINE + MITOMYCIN + RT | 02 | N | HEPATOBLASTOMA SR PLADO | 100957617 |
| 20172887 | 20134564 | 1.72 | 103.8 | null | 2020-04-02 | 2020-04-04 | IPILIMUMAB + NIVOLUMAB | 02 | null | BORTEZOMIB + CYCLOPHOSPHAMIDE | 101667430 |
| 20172987 | 20134565 | 0 | 10.5 | Curative (C) | 2019-07-14 | 2019-07-28 | CAP + RT | N | N | IRINOTECAN + MDG + PANITUMUMAB | 100488470 |
| 20173337 | 20134566 | 1.83 | 68 | Palliative (P) | 2016-09-30 | 2016-10-14 | ABEMACICLIB + FULVESTRANT | 02 | null | CISPLATIN + FU + TRASTUZUMAB | 100025739 |
| 20173661 | 20134567 | null | 79.6 | Disease modification (D) | 2019-12-27 | 2020-03-24 | Paclitaxel albumin (Abraxane) 21day | 01 | N | IXAZOMIB + LENALIDOMIDE | 100515364 |
| 20174214 | 20134569 | 0 | 0 | Adjuvant (A) | 2017-07-23 | 2018-02-13 | CARBOPLATIN + VINORELBINE | 02 | null | INTERAACT TRIAL | 101334088 |
| 20174446 | 20134570 | 1.79 | 77 | Neo-adjuvant (N) | 2015-08-05 | 2015-08-27 | CARBOPLATIN + FLUOROURACIL | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100430350 |
| 20174777 | 20134571 | 1.56 | 0 | Palliative (P) | 2018-08-31 | 2018-11-06 | POMALIDOMIDE | 02 | null | OLARATUMAB | 101564279 |
| 20174811 | 20134572 | 1.77 | 83.8 | Palliative (P) | 2017-02-02 | 2017-12-13 | Bortezomib + Panobinostat | N | N | CARBOPLATIN + VINORELBINE | 100027629 |
| 20175225 | 20134573 | 1.6 | 88 | Palliative (P) | 2018-12-07 | 2018-12-23 | Trabectedin | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101497599 |
| 20175290 | 20134574 | 1.9 | 54.7 | Palliative (P) | null | 2018-04-06 | Hepatoblastoma SR PLADO | null | null | VENETOCLAX | 101297314 |
| 20175696 | 20134575 | 1.46 | 87.4 | Adjuvant (A) | null | 2018-05-19 | Capecitabine + Streptozocin | null | N | SCOPE2 TRIAL | 100154282 |
| 20175860 | 20134577 | 1.65 | 67.4 | Palliative (P) | 2018-07-25 | 2018-08-14 | Carboplatin + Vinorelbine Oral | 02 | N | LIPOSOMAL DOXORUBICIN | 101851228 |
| 20176343 | 20134578 | 1.83 | 63 | Palliative (P) | 2021-11-22 | 2022-04-13 | ETOPOSIDE | N | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100305895 |
| 20176672 | 20134579 | 1.73 | 57 | null | 2018-02-22 | 2018-03-09 | null | 02 | null | EOF | 100764749 |
| 20176772 | 20134580 | 1.81 | 64 | null | 2017-07-28 | 2017-07-29 | CARFILZOMIB + Dexamethasone | 02 | N | INTERAACT TRIAL | 101801059 |
| 20177203 | 20134581 | 1.71 | 51.6 | Neo-adjuvant (N) | 2020-07-18 | 2020-07-18 | Bevacizumab + Oxaliplatin +MdG | 02 | null | ERIBULIN | 100570393 |
| 20177353 | 20134582 | 1.46 | 75.75 | 03 | 2021-07-09 | 2021-07-17 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | CARBOPLATIN + VINORELBINE | 100997655 |
| 20177553 | 20134584 | 1.46 | 74.8 | Neo-adjuvant (N) | 2019-12-02 | 2019-12-09 | Venetoclax | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100565509 |
| 20177749 | 20134585 | 0 | 86.5 | Curative (C) | 2017-09-07 | 2017-09-11 | CARBOPLATIN + GEMCITABINE | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100823814 |
| 20178586 | 20134587 | 1.69 | 51.4 | Palliative (P) | 2022-02-16 | 2022-05-12 | AFATINIB | 02 | N | ACELARATE TRIAL | 101870276 |
| 20178873 | 20134588 | 1.69 | 55.7 | Palliative (P) | null | 2016-10-06 | Bevacizumab + CAPECITABINE + OXALIPLATIN | null | N | CARBOPLATIN + DOCETAXEL | 100843706 |
| 20178883 | 20134589 | 1.81 | 95 | Palliative (P) | 2020-02-14 | 2020-02-26 | PACLITAXEL + RAMUCIRUMAB | 01 | N | BORTEZOMIB + THALIDOMIDE | 100092453 |
| 20179620 | 20134590 | 0 | 8.1 | 03 | 2018-01-02 | 2018-01-04 | RUXOLITINIB | Y | N | SCOPE2 TRIAL | 101588856 |
| 20180081 | 20134591 | 1.79 | 71 | Palliative (P) | 2019-07-01 | 2019-11-13 | CISPLATIN + VINORELBINE + RT | 02 | null | DARATUMUMAB | 100358723 |
| 20180220 | 20134592 | 0 | 46.35 | Neo-adjuvant (N) | 2020-11-05 | 2020-11-19 | Eribulin | 02 | N | FLUOROURACIL + RT | 100550424 |
| 20180262 | 20134593 | 1.78 | 68 | Palliative (P) | 2018-12-22 | 2019-01-17 | Capecitabine+Cisplatin+Streptozocin | N | N | IPILIMUMAB + NIVOLUMAB | 101469714 |
| 20180316 | 20134594 | 1.83 | 78.4 | null | 2018-11-16 | 2018-11-23 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + RT | 100049470 |
| 20180332 | 20134595 | 1.6 | 78.8 | null | 2015-05-26 | 2015-06-10 | Capecitabine + Streptozocin | 02 | N | ECF | 101711506 |
| 20180381 | 20134596 | 1.55 | 66.2 | Curative (C) | 2019-11-24 | 2020-01-01 | CABOZANTINIB | 02 | N | POMALIDOMIDE | 100722021 |
| 20180599 | 20134597 | 1.8 | 20.2 | 03 | 2017-06-10 | 2017-11-18 | Carboplatin + Pemetrexed | Y | N | PERTUZUMAB + TRASTUZUMAB | 100287199 |
| 20180904 | 20134598 | 1.87 | 83.1 | 03 | 2018-01-17 | 2018-01-24 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + Pertuzumab + Trastuzumab | 02 | null | CAPECITABINE + STREPTOZOCIN | 100544999 |
| 20180926 | 20134599 | 1.8 | 89 | Palliative (P) | 2019-09-08 | 2019-09-08 | FCR | 02 | N | HYDROXYCARBAMIDE | 100350853 |